

Patent Claims

Claim 1

Use of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl] phenyl)pyridine-3-sulfonamide or a pharmaceutically acceptable salt thereof, in the production of a drug which is used in the therapy of prostate cancer in a warm blooded animal.

Claim 2

Use of a compound in accordance with Claim 1 or a pharmaceutically acceptable salt thereof, in the production of a drug which is used to induce differentiation of prostate cancer or to lower abnormal proliferation in prostate cancer cells in a warm blooded animal.

Claim 3

Use of a compound in accordance with Claim 1 or a pharmaceutically acceptable salt thereof, in the production of a drug used to induce apoptosis in prostate cancer cells in a warm blooded animal.

Claim 4

Use of a compound in accordance with Claim 1 or a pharmaceutically acceptable salt thereof, in the production of a drug used as an antiangiogenic and vascular targeting agent for the feeder arteries of prostate cancer cells in a warm blooded animal.

Claim 5

Use of a compound in accordance with Claim 1 or a pharmaceutically acceptable salt thereof, in the production of a drug used as an antiangiogenic agent in a warm blooded animal having prostate cancer.

Claim 6

Use in accordance with any one of Claims 1-5, wherein the cancer is in the metastasis stage.

Claim 7

Use in accordance with any one of Claims 1-5, wherein the cancer is in a non-metastasis stage.

Claim 8

Use in accordance with any one of Claims 1-5, wherein the cancer has formed bone metastasis.

Claim 9

Use of a compound in accordance with Claim 1 or a pharmaceutically acceptable salt thereof, in the production of a drug used as an inhibitor of invasion and an inhibitor of bone metastasis in a warm blooded animal having prostate cancer.

Claim 10

Use of a compound in accordance with Claim 1 or a pharmaceutically acceptable salt thereof, in the production of a drug used as an inhibitor of bone metastasis in a warm blooded animal having prostate cancer.

Claim 11

Use of a compound in accordance with Claim 1 or a pharmaceutically acceptable salt thereof, in the production of a drug used to prevent bone metastasis in a warm blooded animal having prostate cancer.

Claim 12

Use of a compound in accordance with Claim 1 or a pharmaceutically acceptable salt thereof, in the production of a drug used for the therapy of bone metastasis in a warm blooded animal having prostate cancer.

Claim 13

Use in accordance with any one of Claims 1 – 12, wherein the warm blooded animal is human.

Claim 14

A prostate cancer therapeutic agent containing N-(3-methoxy-5-methylpyrazin -2-yl)-2-(4-[1,3,4-oxadiazol-2-yl] phenyl)pyridine-3-sulfonamide or a pharmaceutically acceptable salt thereof as an active component.

Claim 15

A cancer therapeutic agent in accordance with Claim 14, which induces differentiation of prostate cancer cells or reduces abnormal proliferation in prostate cancer cells.

Claim 16

A cancer therapeutic agent in accordance with Claim 14, which induces apoptosis in prostate cancer cells.

Claim 17

A cancer therapeutic agent in accordance with Claim 14, which is an antiangiogenic and vascular targeting agent for prostate cancer cell feeder arteries.

Claim 18

A cancer therapeutic agent in accordance with Claim 14, which is an antiangiogenic agent.

Claim 19

A cancer therapeutic agent in accordance with any one of Claims 14-18, wherein the prostate cancer is in the metastasis stage.

Claim 20

A cancer therapeutic agent in accordance with any one of Claims 14-18, wherein the prostate cancer is in a non-metastasis stage.

Claim 21

A cancer therapeutic agent in accordance with any one of Claims 14-18, wherein the prostate cancer has formed bone metastasis.

Claim 22

A cancer therapeutic agent in accordance with Claim 14, which is a bone metastasis inhibitor and an invasion inhibitor.

Claim 23

A cancer therapeutic agent in accordance with Claim 14, which is a bone metastasis inhibitor.

Claim 24

A cancer therapeutic agent in accordance with Claim 14, which is a metastasis preventative agent.

Claim 25

A cancer therapeutic agent in accordance with Claim 14, which is a therapeutic agent for bone metastasis.

Rising Sun Communications Ltd. Terms and Conditions (Abbreviated)

Rising Sun Communications Ltd. shall not in any circumstances be liable or responsible for the accuracy or completeness of any translation or given written opinion unless such an undertaking has been given and authorised by Rising Sun Communications Ltd. in writing beforehand. More particularly, Rising Sun Communications Ltd. shall not in any circumstances be liable for any direct, indirect, consequential or financial loss or loss of profit resulting directly or indirectly from the use of any translation or consultation services by the customer.

Rising Sun Communications Ltd. retains the copyright to all of its' translation products unless expressly agreed in writing to the contrary. The original buyer is permitted to reproduce copies of a translation for their own corporate use at the site of purchase, for their own patent filing purposes, and for their own client needs, however other publication in written or electronic format for resale or other dissemination to a wider audience is strictly forbidden unless by prior written agreement.

The Full Terms and Conditions of Business of Rising Sun Communications Ltd. may be found at the web site address <http://www.risingsun.co.uk/Terms_of_business.html>